ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Bought by AssuredPartners Investment Advisors LLC

AssuredPartners Investment Advisors LLC increased its position in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 133.4% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 69,111 shares of the company's stock after buying an additional 39,500 shares during the period. AssuredPartners Investment Advisors LLC owned 0.07% of ARS Pharmaceuticals worth $869,000 as of its most recent filing with the SEC.

Other institutional investors have also recently modified their holdings of the company. Wellington Management Group LLP grew its position in shares of ARS Pharmaceuticals by 0.6% in the fourth quarter. Wellington Management Group LLP now owns 163,252 shares of the company's stock valued at $1,722,000 after purchasing an additional 917 shares during the period. Rhumbline Advisers boosted its holdings in ARS Pharmaceuticals by 2.9% in the 4th quarter. Rhumbline Advisers now owns 65,163 shares of the company's stock worth $687,000 after buying an additional 1,824 shares during the last quarter. Mariner LLC increased its stake in ARS Pharmaceuticals by 5.8% during the 4th quarter. Mariner LLC now owns 35,908 shares of the company's stock worth $379,000 after buying an additional 1,972 shares in the last quarter. LPL Financial LLC raised its holdings in shares of ARS Pharmaceuticals by 11.4% during the fourth quarter. LPL Financial LLC now owns 21,408 shares of the company's stock valued at $226,000 after acquiring an additional 2,190 shares during the last quarter. Finally, Bernard Wealth Management Corp. purchased a new position in shares of ARS Pharmaceuticals in the fourth quarter valued at approximately $27,000. 68.16% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on SPRY. Wall Street Zen cut ARS Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. William Blair reiterated an "outperform" rating on shares of ARS Pharmaceuticals in a report on Monday, March 3rd. Finally, Scotiabank assumed coverage on shares of ARS Pharmaceuticals in a report on Friday, March 7th. They issued a "sector outperform" rating and a $30.00 price objective for the company. One research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $31.00.

Insider Buying and Selling

In related news, insider Eric Karas sold 15,000 shares of ARS Pharmaceuticals stock in a transaction that occurred on Wednesday, June 18th. The shares were sold at an average price of $16.00, for a total value of $240,000.00. Following the completion of the transaction, the insider now owns 7,696 shares in the company, valued at $123,136. The trade was a 66.09% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Laura Shawver sold 50,002 shares of the firm's stock in a transaction on Monday, April 7th. The shares were sold at an average price of $12.30, for a total transaction of $615,024.60. Following the completion of the sale, the director now owns 210,346 shares in the company, valued at $2,587,255.80. The trade was a 19.21% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 337,971 shares of company stock valued at $4,721,888 in the last three months. 33.50% of the stock is owned by corporate insiders.

ARS Pharmaceuticals Price Performance

ARS Pharmaceuticals stock opened at $16.78 on Wednesday. The company has a debt-to-equity ratio of 0.30, a quick ratio of 10.74 and a current ratio of 11.00. The company has a market capitalization of $1.65 billion, a price-to-earnings ratio of -104.87 and a beta of 0.84. The company's 50 day simple moving average is $14.45 and its 200-day simple moving average is $12.92. ARS Pharmaceuticals, Inc. has a 1 year low of $7.55 and a 1 year high of $18.51.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($0.35) EPS for the quarter, meeting analysts' consensus estimates of ($0.35). The company had revenue of $7.97 million during the quarter, compared to analysts' expectations of $7.48 million. ARS Pharmaceuticals had a negative return on equity of 6.94% and a negative net margin of 16.11%. As a group, equities research analysts expect that ARS Pharmaceuticals, Inc. will post -0.55 earnings per share for the current year.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.